

## BTK inhibitors in CLL and MCL: Strategies for Managing Adverse Events

### References

1. Ghia P, Pluta A, Wach M, et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. *J Clin Oncol*. 2020;38(25):2849-2861.
2. Hillmen P, Eichhorst B, Brown JR, et al. First interim analysis of Alpine study: Results of a phase 3 randomized study of zanubrutinib vs. ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia. LB1900. Data presented at the European Hematology Association 2021 meeting. <https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/330170/peter.hillmen.first.interim.analysis.of.alpine.study.results.of.a.phase.3.html>. Accessed September 13, 2021.
3. Kaptein Y, De Bruin G, Emmelot-van Hoek M, van de Kar B. Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies. *Blood*. 2018;132(Supplement 1):1871.
4. Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. *J Clin Oncol*. 2021 July 26 [Epub ahead of print].
5. Barr P, Brown JR, Hillmen P, et al. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. *Blood*. 2017;129(19):2612-2615.
6. Mato A, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: A real-world analysis. *Haematologica*. 2018;103(5):874-879.
7. Aarup K, Curovic Rotbain E, Enggaard L, et al. Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. *Eur J Haem*. 2020;105(5):646-654.
8. Hardy-Abeloos C, Pinotti R, Gabrilove J. Ibrutinib dose modifications in the management of CLL. *J Hematol Oncol*. 2020;13(1):66.
9. Ganatra S, Sharma A, Shah S, et al. Ibrutinib-Associated Atrial Fibrillation. *JACC: Clinical Electrophysiology*. 2018; 4(12):1491-1500.
10. Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. *N Engl J Med*. 2014;371(3):213-223.
11. Rhodes J, LoRe VA, Mato AR, et al. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. *Clin Lymphoma Myeloma Leuk*. 2020;20(7):438-444.e1.
12. Lipsky A, Lozier JN, Wiestner A. Response to Comment on Incidence and Risk Factors of Bleeding-Related Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. *Haematologica*. 2016;101(3):e124-125.

13. O'Brien S, Hillmen P, Coutre S, et al. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2018;18(10):648-657.e15.
14. Sharman J, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. *Lancet*. 2020;395(10232):1278-1291.
15. Coutre SE, Byrd JC, Hillmen P, et al. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. *Blood Adv*. 2019;3(12):1799-1807.
16. Rogers K, Mousa L, Zhao Q, et al. Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies. *Leukemia*. 2019;33(10):2527-2530.
17. Ryan C, Cheng MP, Issa NC, et al. Pneumocystis jirovecii pneumonia and institutional prophylaxis practices in CLL patients treated with BTK inhibitors. *Blood Adv*. 2020;4(7):1458-1463.
18. Blood Cancers Diminish Response to COVID-19 Vaccine. *Cancer Discov*. 2021;11(7):OF4.